• Publications
  • Influence
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
TLDR
The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced melanoma.
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
TLDR
In patients with advanced melanoma, including those who had had disease progression while they had been receiving ipilimumab, treatment with lambrolizumab resulted in a high rate of sustained tumor regression, with mainly grade 1 or 2 toxic effects.
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
TLDR
Dabrafenib and trametinib were safely combined at full monotherapy doses, and the rate of pyrexia was increased with combination therapy, whereas the rates of proliferative skin lesions was nonsignificantly reduced.
A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments
TLDR
The studies reveal that innate immune SDCs and NK cells cluster together as an excellent prognostic tool for T cell–directed immunotherapy and that these innate cells are necessary for enhanced T cell tumor responses, suggesting this axis as a target for new therapies.
The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis
TLDR
The gene expression profiling of primary, non-metastatic cutaneous tumors and metastatic melanoma has resulted in the identification of several genes that may be centrally involved in the progression and metastasis potential of melanoma.
Roles of activated Src and Stat3 signaling in melanoma tumor cell growth
TLDR
It is demonstrated that Stat3 is constitutively activated in a majority of human melanoma cell lines and tumor specimens examined and that Src-activated Stat3 signaling is important for the growth and survival of melanoma tumor cells.
Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.
TLDR
The absence of severe toxicities, attainment of plasma concentrations active in preclinical models, and compelling antitumor activity warrant further disease-directed studies of this agent alone and in combination with chemotherapy in a broad array of tumors.
...
...